

INFORMAZIONI PERSONALI

Emanuela Pillozzi

Nata a Roma 17/05/1968

Domicilio Via A. Vivaldi 12, 00199 Roma

✉ emanuela.pillozzi@uniroma1.it

POSIZIONE RICOPERTA

- 01/09/2015 ad oggi Professore Associato di Anatomia Patologica (MED08)
Sapienza Università di Roma

-12/03/2001 ad oggi Strutturazione assistenziale come Dirigente di I livello UOC
Anatomia Patologica Azienda Ospedaliero-Universitaria Sant'Andrea, Via di
Grottarossa 1035, 00189 Roma

ISTRUZIONE E FORMAZIONE

-25/10/1993 Laurea in Medicina e Chirurgia, Università "La Sapienza" Roma

-19/11/1997 Specializzazione in Anatomia Patologica, Università "La Sapienza", Roma

Esperienze all'estero

(da 12/1996 a 05/1998)

Research Fellow University of Oxford (UK), Dept of Cellular Science (Prof. K. Gatter)

(da 13/08/2007 a 07/09/2007)

Visiting Doctor University of Birmingham (UK) Dept of Pathology, (Prof. S Hubsher)

ATTIVITA' DIDATTICA

- Corso di Laurea Magistrale Medicina e Chirurgia, Facoltà di Medicina e Psicologia, Università "La Sapienza"
- Corso di Laurea triennale Tecnico di laboratorio Biomedico (codice corso 30020), Università "La Sapienza", Dipartimento di Medicina Clinica e Molecolare
- Corso di laurea Triennale Infermieristica Celio/ex CRI (codice corso 28742), Università "La Sapienza", Dipartimento di Medicina Clinica e Molecolare
- Componente del collegio di Dottorato in Oncologia- (coordinatore Prof. Bruno Annibale), Università "La Sapienza" Roma
- Docente Scuola di Specializzazione in Anatomia Patologica , Università "La Sapienza" Roma
- Docente Scuola di Specializzazione in Malattie dell'Apparato Digerente , Università "La Sapienza" Roma
- Docente Scuola di Specializzazione in Chirurgia Generale , Università "La Sapienza" Roma

Dati personali Autorizzo il trattamento dei miei dati personali ai sensi del Decreto Legislativo 30 giugno 2003, n. 196 "Codice in materia di protezione dei dati personali".

Prof.ssa
Emanuela Pillozzi



ALLEGATI

Elenco pubblicazioni in extenso
Numero: 103
H-index: 27 (Scopus, Novembre 2020)

PUBBLICAZIONI DOTT.SSA EMANUELA PILOZZI Aggiornato Novembre 2020

1. M-Padura I, De Castellarnau C, Uccini S, **Pillozzi E**, Natali PG, Nicotra MR, Ughi F, Azzolini C, Dejana E, Ruco LP: Expression of VE (vascular endothelial)-cadherin and other endothelial-specific markers in haemangiomas. *J Pathol* 1995, 175:51-7 (IF= 5.759)
2. Ruco LP, Uccini S, Stoppacciaro A, **Pillozzi E**, Morrone S, Gallo A, De Vincentis M, Santoni A, Baroni CD: The lymphoepithelial organization of the tonsil: an immunohistochemical study in chronic recurrent tonsillitis. *J Pathol* 1995, 176:391-8. (IF= 5.759)
3. Uccini S, **Pillozzi E**, Stoppacciaro A, Sirianni MC, Vicenzi L, Angeloni A, Santarelli R, Faggioni A, Cerimele D, Masala MV, Cottoni F, Baroni CD, Ruco LP: Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 is not detectable in peripheral blood mononuclear cells of the relatives of sporadic KS patients. *J Invest Dermatol* 1997, 108(1):119-20 (IF= 4.535)
4. **Pillozzi E**, Stoppacciaro A, Rendina E, Ruco LP: Monocyte chemotactic protein-1 in the inflammatory pseudotumour of the lung. *Mol Pathol* 1998, 51(1):50-2. (IF= 2.245)
5. Ruco LP, Pillozzi E, Martine Wedard B, Marzullo A, D'Andrea V, De Antoni E, Silvestrini G, Bonetti F: Epithelioid lymphangioliomyomatosis-like tumour of the uterus in a patient without tuberous sclerosis: a lesion mimicking epithelioid leiomyosarcoma. *Histopathology* 1998, 33(1):91-3. (IF= 3.216)
6. **Pillozzi E**, Fidler C, Boulwood J, Wainscoat JS: BRCA2 gene deletion is rare in chronic lymphocytic leukemia. *Am J Hematol* 1998, 59(4):318. (IF= 1.882)
7. **Pillozzi E**, Pulford K, Jones M, Müller-Hermelink HK, Falini B, Ralfkier E, Pileri S, Pezzella F, De Wolf-Peeters C, Arber D, Stein H, Mason D, Gatter K: Co-expression of CD79a (JCB117) and CD3 by lymphoblastic lymphoma. *J Pathol* 1998, 186(2):140-3. (IF= 5.759)

8. **Pillozzi E**, Müller-Hermelink HK, Falini B, De Woolf-Peeters C, Fidler C, Gatter K, Wainscoat J: Gene rearrangements in T-cell lymphoblastic lymphoma. *J Pathol* 1999, 188(3):267-70. (IF= 5.759)
9. **Pillozzi E**, Talerico C, Platt A, Fidler C, Ruco LP: p73 gene mutations in gastric adenocarcinomas. *Mol Pathol* 2003 Feb;56(1):60-2. (IF= 2.245)
10. **Pillozzi E**, Talerico C, Uccini S, Adesso M, Rossi R, Vago L, Antinori A, Ruco LP: B cell clonality in multiple localizations of primary central nervous system lymphomas in AIDS patients. *Leuk Lymphoma* 2003, 44(6):963-6. (IF= 1.559)
11. Ruco LP, Di Napoli A, **Pillozzi E**, Talerico C, Uccella I, Giancola ML, Alba L, Antinori A: Peripheral T cell lymphoma with cytotoxic phenotype: an emerging disease in HIV-infected patients. *AIDS Res Hum Retroviruses* 2004, 20(2):129-33. (IF= 2.513)
12. Scarpino S, Di Napoli A, Rapazzotti Onelli M, **Pillozzi E**, Ruco L: Papillary carcinoma of the thyroid: methylation is not involved in the regulation of MET expression. *Br J Cancer* 2004, 16;91(4):703-6. (IF= 4.459)
13. Lahner E, Vaira D, Figura N, **Pillozzi E**, Pasquali A, Severi C, Perna F, Delle Fave G, Annibale B: Role of noninvasive tests (C-urea breath test and stool antigen test) as additional tools in diagnosis of Helicobacter pylori infection in patients with atrophic body gastritis. *Helicobacter* 2004; 9(5):436-42. (IF= 2.477)
14. **Pillozzi E**, Rapazzotti Onelli M, Ziparo V, Mercantini P, Ruco L: CDX1 expression is reduced in colorectal carcinoma and is associated with promoter hypermethylation. *J Pathol* 2004, 204(3):289-95. (IF= 5.759)
15. Larussa D, Grisetti S, **Pillozzi E**, Concorsi P, Pisa R, Ruco L, Antinori A: Acute megakaryoblastic leucemia in a patient receiving HAART. *Am J Hematol* 2005, 80: 89-90 (IF= 1,882)
16. Corleto VD, Zykaj E, Mercantini P, **Pillozzi E**, Rossi M, Carniccio A, Di Giulio E, Riparo V, Delle Fave G: Is colonoscopy sufficient for colorectal cancer surveillance in all HNPCC patients? *World J Gastroenterol* 2005, 11 47: 7541-44.
17. Eramo A, Ricci-Vitiani L, Pallini R, Zeuner A, Lotti F, Sette G, **Pillozzi E**, Larocca LM, Peschle C, De Maria R: Chemotherapy resistance of glioblastoma stem cells. *Cell Death Differ* 2006, 13(7):1238-41 (IF= 7.463)
18. Ramacciato G, Nigri GR, Aurello P, D'Angelo F, Pezzoli F, Rossi S, **Pillozzi E**, Ercolani G, Ravaioli M: Giant hepatic adenoma with bone marrow metaplasia not associate with oral contraceptive intake. *W J Surg Oncol* 2006, 4: 58
19. Ramacciato G, Nigri G, D'Angelo F, Aurello P, Bellagamba R, Colarossi C, **Pillozzi E**, Del Gaudio M: Emergency laparotomy for misdiagnosed biliary cystadenoma originating from caudate lobe. *World J Surg Oncol*. 2006 Nov 7;4:76.
20. Ricci-Vitiani L, Lombardi D, **Pillozzi E**, Biffoni M, Todaro M, Peschle C, De Maria R: Identification, isolation and expansion of human colon cancer initiating cells. *Nature*, 2007, 445:111-115 (IF= 26.681)

21. Scarpino S, Di Napoli A, Stoppacciaro A, Antonelli M, **Pilozzi E**, Chiarle R, Palestro G, Marino M, Facciolo F, Rendina EA, Webster KE, Kinkel SA, Scott HS, Ruco L. Expression of autoimmune regulator gene (AIRE) and T regulatory cells in human thymomas. *Clin Exp Immunol.* 2007;149:504-12. (IF= 2.747)
22. Cavallini M, Cavaniglia D, Felicioni F, Vitale V, **Pilozzi E**, Ziparo V. Large periampullary villous tumor of the duodenum. *J Hepatobiliary Pancreat Surg.* 2007;14:526-8. (IF= 1.182)
23. Eramo A, Lotti F, Sette G, **Pilozzi E**, Biffoni M, Di Virgilio A, Conticello C, Ruco L, Peschle C, De Maria R. Identification and expansion of the tumorigenic lung cancer stem cell population. *Cell Death Differ.* 2008, 15:504-14. (IF= 7.463)
24. Luong TV, **Pilozzi E**, Bearzi I, Bordi C. Mucosal colonization of gastric endocrine tumors mimicking mixed neoplasms. *Virchows Arch*, 2008, 452:169-74. (IF= 2.251)
25. Petrocca F, Visione R, Onelli RM, Shah MH, Nicoloso MS, de Martino I, Iliopoulos D, **Pilozzi E**, Liu CG, Negrini M, Cvazzini L, Volinia S, Alder H, Ruco LP, Baldassarre G, Croce CM, secchione A. E2F1- regulated microRNAs impari TGFbeta-dependent cell cycle arrest and apoptosis in gastric cancer. *Cancer Cell* 2008, 13: 272-286 (IF=24).
26. Melotti F, Mari E, Giorgiana F, Fidanza L, Carlesimo M, **Pilozzi E**, Raffa E, Camplone G, Bartolazzi A. Actinic Reticulosis with clonal TCR (T-cell receptor) gene rearrangement. *Eur J Dermatol* 2008, 18: 598-600. (IF: 1,175)
27. Scarpino S, Duranti E, Stoppacciaro A, **Pilozzi E**, Natoli G, Sciacchitano S, Luciani E, Ruco L. COX-2 is induced by HGF stimulation in Met-positive thyroid papillary carcinoma cells and is involved in tumour invasiveness. *J Pathol* 2009, 218: 487.(IF: 5,121)
28. **Pilozzi E**, Del Prete F, De Dominicis C, Angelo Rendina E, P Ruco L. True thymic hyperplasia associated with thymic hemorrhage in an adult patient. *Pathol Res Pract* 2009.(IF: 1,029)
29. Muroli M, D'Angelo F, Pezzatini M, Sebastiani S, Noto S, **Pilozzi E**, Ramacciato G. Synchronous gastric adenocarcinoma and pancreatic ductal adenocarcinoma. *Hepatobiliary Pancreat Dis Int.* 2010 Feb;9(1):97-9.(IF: 1,183)
30. Baiocchi M, Biffoni M, Ricci-Vitiani L, **Pilozzi E**, De Maria R. New models for cancer research: human cancer stem cell xenografts. *Curr Opin Pharmacol.* 2010 Aug;10(4):380-384. (IF:7,259)
31. Ricci-Vitiani L, Mollinari C, di Martino S, Biffoni M, **Pilozzi E**, Pagliuca A, Chiara de Stefano M, Circo R, Merlo D, De Maria R, Garaci E. Thymosin {beta}4 targeting impairs tumorigenic activity of colon cancer stem cells. *FASEB J.* 2010 24(11): 4291-301. (IF: 6,4)
32. Lorenzon L, Ferri M, **Pilozzi E**, Torrisi MR, Ziparo V, French D. Human papillomavirus and colorectal cancer: evidences and pitfalls of published literature. *Int J Colorectal Dis.* 2011, 26:135-142.(IF: 2.10)
33. Vannella L, Lahner E, Bordi C, **Pilozzi E**, Di Giulio E, Corleto VD, Osborn J, Delle Fave G, Annibale B. Reversal of atrophic body gastritis after H. pylori eradication at long-term follow-up. *Dig Liver Dis.* 2011 43:295-299 (IF:2.97)

34. La Torre M, Ferrari L, Cosenza G, Nava AK, Mercantini P, Pasanen A, **Pilozzi E**, Ziparo V. Esophageal small cell carcinoma. *Am Surg* 2010 76: 28-30. (IF: 1,154)
35. **Pilozzi E**, Ferri M, Rapazzotti Onelli M, Mercantini P, Corigliano N, Duranti E, Dionisi L, Felicioni F, Virgilio E, Ziparo V, Ruco L. Prognostic significance of 18q LOH in sporadic colorectal carcinoma. *Am Surg* 2011 77: 38-43. (IF: 1,154)
36. Caterino S, Lorenzon L, Petrucciani N, Iannicelli E, **Pilozzi E**, Romiti A, Cavallini M, Ziparo V. Gastrointestinal stromal tumors: correlation between symptoms at presentation, tumor location and prognostic factors in 47 consecutive patients. *World J Surg Oncol* 2011, 9:13 (IF:1,1)
37. Pagnini C, Corleto VD, Mangoni ML, **Pilozzi E**, Torre MS, Marchese R, Carnuccio A, Giulio ED, Fave GD. Alteration of Local Microflora and α -defensins Hyper-production in Colonic Adenoma Mucosa. *J Clin Gastroenterol*. 2011 Feb 22. [Epub ahead of print] (IF: 2,207)
38. Rugge M, Pennelli G, **Pilozzi E**, Fassan M, Ingravallo G, Russo VM, Di Mario F Gastritis: the histology report. *Dig Liver Dis*. 2011 Mar;43 Suppl 4:S373-84. (IF: 2,97)
39. L Vannella, A Sbrozzi-Vanni, E Lahner, C Bordi, E Pilozzi, V D Corleto , G Delle Fave, B Annibale. Development of Type I Gastric Carcinoid in patients with Chronic atrophic gastritis. *Alimentary Pharmacology & Therapeutics* 2011, 33(12): 1361-69. (IF: 4.3)
40. Di Florio A, Adesso L, Pedrotti S, Capurso G, **Pilozzi E**, Corbo V, Scarpa A, Geremia R, Delle Fave G, Sette C. Src kinase activity coordinates cell adhesion and spreading with activation of mTOR in pancreatic endocrine tumor cells. *Endocr Relat Cancer*. 2011 Jun 28. 18(5):541-54 (IF:4.36)
41. Merola E, Sbrozzi-Vanni A, Panzuto F, D'Ambra G, Di Giulio E, **Pilozzi E**, Capurso G, Lahner E, Bordi C, Annibale B, Delle Fave G. Type I Gastric Carcinoids: A Prospective Study on Endoscopic Management and Recurrence Rate. *Neuroendocrinology*. 2012, 95:207-13. (IF:2,37)
42. **Pilozzi E**, Cacchi C, Di Napoli A, Pini B, Duranti E, D'Andrilli A, Ruco L. Primary malignant tumour of the lung with neuroendocrine and melanoma differentiation. *Virchows Arch*. 2011 ;459(2):239-43. (IF: 2,49)
43. Iannicelli E, Saporì A, Panzuto F, **Pilozzi E**, Delle Fave G, David V. Oesophageal GIST: MDCT Findings of Two Cases and Review of the Literature. *J Gastrointest Cancer*. 2012, 43: 481-85.
44. Bartucci M, Svensson S, Romania P, Dattilo R, Patrizii M, Signore M, Navarra S, Lotti F, Biffoni M, **Pilozzi E**, Duranti E, Martinelli S, Rinaldo C, Zeuner A, Maugeri-Saccà M, Eramo A, De Maria R. Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy. *Cell Death Differ*. 2012, 19:768-778. (IF: 8,84)
45. La Torre M, Lorenzon L, **Pilozzi E**, Barucca V, Cavallini M, Ziparo V, Ferri M. Number of harvested lymph nodes is the main prognostic factor in Stage IIa colorectal cancer patients. *J Surg Oncol*. 2012, 106: 469-474. (IF: 2,1)
46. Lorenzon L, **Pilozzi E**, La Torre M, Ziparo V, Ferri M. Impact and prognostic implications of colon cancers stage II sub-classification through the years. *Int J Colorectal Dis*. 2012, 27: 1311-8. (IF: 2,38)

47. Virgilio E, Pucci E, **Pilozzi E**, Mongelli S, Cavallini M, Ferri M. Reactive nodular fibrous pseudotumor of the gastrointestinal tract and mesentery giving multiple hepatic deposits and associated with colon cancer. *Am Surg.* 2012 May;78(5):262-4 (IF: 1,154)
48. Lorenzon L, Ziparo V, Cavaniglia D, **Pilozzi E**, Iannicelli E, Caterino S. Clinical-pathological features of gastrointestinal stromal tumors presenting associated with other neoplasms: a brief report. *Minerva Chir.* 2012 Apr;67(2):175-80.
49. Aurello P, Petrucciani N, D'Angelo F, **Pilozzi E**, Pulcini F, Cicchini C, Nigri GR, Ramacciato G. Squamous cell carcinoma of the pancreas presenting with upper gastrointestinal bleeding. *Am Surg.* 2012 May;78(5):284-5. (IF: 1,154)
50. Adesso L, Calabretta S, Barbagallo F, Capurso G, **Pilozzi E**, Geremia R, Delle Fave G, Sette C. Gemcitabine triggers a pro-survival response in pancreatic cancer cells through activation of the MNK2/eIF4E pathway. *Oncogene.* 2013, 32:2848-57 (IF:6,37)
51. Corleto VD, Pagnini C, Cattaruzza MS, Zykaj E, Di Giulio E, Margagnoni G, **Pilozzi E**, D'Ambra G, Lamazza A, Fiori E, Ferri M, Masoni L, Ziparo V, Annibale B, Delle Fave G. Is proliferative colonic disease presentation changing? *World J Gastroenterol.* 2012 Dec 7;18(45):6614-9. (IF:2.54)
52. Lorenzon L, Castaldo P, Bartolazzi A, Rossi Del Monte S, Camboni A, **Pilozzi E**, Salvi PF, Ziparo V. Debating the presentation, morphology, origin, and prognosis of a combined hepatocellular-cholangiocarcinoma. *Dig Dis Sci.* 2013 Aug;58(8):2423-4. (IF:2.26)
53. Ferri M, Lorenzon L, Onelli MR, La Torre M, Mercantini P, Virgilio E, Balducci G, Ruco L, Ziparo V, **Pilozzi E**. Lymph node ratio is a stronger prognostic factor than microsatellite instability in colorectal cancer patients: Results from a 7 years follow-up study. *Int J Surg.* 2013;11(9):1016-21. (IF:1,436)
54. Vinciguerra GL, Mercantini P, La Torre M, **Pilozzi E**, Ziparo V, Vecchione A. Transitional Cell Carcinoma of the Retrorectal Space Arisen in Tailgut Cyst: A Case Report and Review of the Literature. *Int J Surg Pathol.* 2013, 22:280-85.(IF: 0.76)
55. Di Napoli A, Al-Jadiri MF, Talerico C, Duranti E, **Pilozzi E**, Trivedi P, Anastasiadou E, Alsaadawi AR, Al-Darraj AF, Al-Hadad SA, Testi AM, Uccini S, Ruco L. Epstein-Barr virus (EBV) positive classical Hodgkin lymphoma of Iraqi children: an immunophenotypic and molecular characterization of Hodgkin/Reed-Sternberg cells. *Pediatr Blood Cancer.* 2013 Dec;60(12):2068-72. (IF: 2.35)
56. Sette G, Fecchi K, Salvati V, Lotti F, **Pilozzi E**, Duranti E, Biffoni M, Pagliuca A, Martinetti D, Memeo L, Milella M, De Maria R, Eramo A. Mek inhibition results in marked antitumor activity against metastatic melanoma patient-derived melanospheres and in melanosphere-generated xenografts. *J Exp Clin Cancer Res.* 2013 Nov 16;32(1):91 (IF:3)
57. Lahner E, **Pilozzi E**, Esposito G, Galli G, Annibale B. Gastric carcinoid in the absence of atrophic body gastritis and with low Ki67 index: a clinical challenge. *Scand J Gastroenterol* 2014, 49:1447-55 (IF: 2.1)
58. Lorenzon L, Mercantini P, Ferri M, La Torre M, Sparagna A, Balducci G, Tarantino G, Romiti A, **Pilozzi E**, Ziparo V. Profiling the prognosis of gastric cancer patients: is it worth correlating the survival with the clinical/pathological and molecular features of gastric cancers? *Scientific World Journal.* 2013 Dec 24;2013:196541.(IF:1.7)

59. Iannicelli E, Di Renzo S, Ferri M, **Pilozzi E**, Di Girolamo M, Saponi A, Ziparo V, David V. Accuracy of high-resolution MRI with lumen distention in rectal cancer staging and circumferential margin involvement prediction. *Korean J Radiol* 2014, 15:37-44 (IF:1.5)
60. Panzuto F, Merola E, Rinzivillo M, Partelli S, Campana D, Iannicelli E, **Pilozzi E**, Mercantini P, Rossi M, Capurso G, Scarpa A, Cascinu S, Tomassetti P, Falconi M, Delle Fave G. Advanced digestive neuroendocrine tumors: metastatic pattern is an independent factor affecting clinical outcome. *Pancreas* 2014 Mar;43(2):212-8. (IF:2.9)
61. Bartucci M, Dattilo R, Moriconi C, Pagliuca A, Mottolise M, Federici G, Benedetto AD, Todaro M, Stassi G, Sperati F, Amabile MI, **Pilozzi E**, Patrizii M, Biffoni M, Maugeri-Saccà M, Piccolo S, De Maria R. TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells. *Oncogene*. 2014 Feb 17. doi: 10.1038/onc.2014.5. (IF:7.35)
62. Lahner E, Esposito G, **Pilozzi E**, Galli G, Corleto VD, Di Giulio E, Annibale B. Gastric cancer in patients with type I gastric carcinoids. *Gastric Cancer*. 2014 Jun 3. [Epub ahead of print] (IF: 4.8)
63. Anania G, Gigante E, Piciocchi M, **Pilozzi E**, Pucci E, Pellicelli AM, Capotondi C, Rossi M, Baccini F, Antonelli G, Begini P, Delle Fave G, Marignani M. Liver biopsy: Analysis of results of two specialist teams. *World J Gastrointest Pathophysiol*. 2014 May 15;5(2):114-9.
64. Galli G, Esposito G, Lahner E, **Pilozzi E**, Corleto VD, Di Giulio E, Aloe Spiriti MA, Annibale B. Histological recovery and gluten-free diet adherence: a prospective 1-year follow-up study of adult patients with coeliac disease. *Aliment Pharmacol Ther*. 2014 40(6):639-47. (IF: 5.4)
65. La Torre M, Nigri G, Mazzuca F, Ferri M, Botticelli A, Lorenzon L, **Pilozzi E**, Ziparo V. Standard versus limited colon resection for high risk T1 colon cancer. A matched case-control study. *J Gastrointest Liver Dis* 2014, 23(3):285-90. (IF: 1.9)
66. Lahner E, Galli G, Esposito G, **Pilozzi E**, Corleto VD, Annibale B. Updated features associated with type 1 gastric carcinoids patients: a single-center study. *Scand J Gastroenterol*. 2014, 13:1-9 (IF: 2.33)
67. Lorenzon L, Mazzetta F, **Pilozzi E**, Uggeri G, Torrisi MR, Ferri M, Ziparo V, French D. Human Papilloma Virus does not have a casual role in colorectal carcinoma. *World Journal of Gastroenterology* 2015, 21:342-350. (IF:2.47)
68. Lahner E, Esposito G, **Pilozzi E**, Purchiaroni F, Corleto VD, Di Giulio E, Annibale B. Occurrence of gastric cancer and carcinoids in atropi gastritis during prospective long-term follow up *Scand J Gastroenterol* 2015, 50:856-865.
69. **Pilozzi E**, Maresca C, Duranti E, Giustiniani MC, Catalanotto C, Lucarelli M, Cogoni C, Ferri M, Ruco L, Zardo G. Left-sided early onset versus late onset colorectal carcinomas: histological, clinical and molecular differences. *American Journal of Clinical Pathology* 2015, 143:1-11 (IF:3.1).
70. Di Pietropaolo M, Briani C, **Pilozzi E**, Carbonetti F, David V, Iannicelli E. Gd-EOB-DTPA-Enhanced Magnetic Resonance finding of a giant inflammatory hepatocellular adenoma: a case report and review of the literature. *J Gastrointest Cancer* 2015
71. Calabretta S, Bielli P, Passacantilli I, **Pilozzi E**, Fendrich V, Capurso G, Fave GD, Sette C. Modulation of PKM alternative splicing by PTBP1 promotes gemcitabine resistance in pancreatic cancer cells. *Oncogene*, 2015 (IF:8.4)

72. Sette G, Salvati V, Mottolese M, Visca P, Gallo E, Fecchi K, **Pillozzi E**, Duranti E, Policicchio E, Tartaglia M, Milella M, De Maria R, Eramo A. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer. *Cell Death Dis*, 2015 (IF: 5)
73. Lahner E, Esposito G, Angeletti S, Corleto VD, **Pillozzi E**, Di Giulio E, Annibale B. Endoscopic appearances of polypoid type 1 gastric microcarcinoids by narrow-band imaging: a case series in a referral center. *Europ J Gastroenterol Hepathol* 2016 Jan 7. [Epub ahead of print] (IF: 2.25)
74. De Angelis ML, Zeuner A, Policicchio E, Russo G, Bruselles A, Signore M, Vitale S, De Luca G, **Pillozzi E**, Boe A, Stassi G, Ricci-Vitiani L, Amoreo CA, Pagliuca A, Francescangeli F, Tartaglia M, De Maria R, Baiocchi M. Cancer Stem Cell-Based Models of Colorectal Cancer Reveal Molecular Determinants of Therapy Resistance. *Stem Cells Transl Med*. 2016 Apr;5(4):511-23. doi: 10.5966/sctm.2015-0214.
75. Pescatori LC, Festa S, Panzuto F, **Pillozzi E**, Prosperi D, Rinzivillo M, Pizzichini P, Iaquinto G, Iannicelli E, Mené P, Delle Fave G, Capurso G. A Case of Pancreatic Small Cell Neuroendocrine Carcinoma Associated With SIADH. *Pancreas*. 2016 May-Jun;45(5):e20-2. doi: 10.1097/MPA.0000000000000558
76. Rossi S, Sbaraglia M, Dell'Orto MC, Gasparotto D, Cacciatore M, Boscato E, Carraro V, Toffolatti L, Gallina G, Niero M, **Pillozzi E**, Mandolesi A, Sessa F, Sonzogni A, Mancini C, Mazzoleni G, Romeo S, Maestro R, Dei Tos AP. Concomitant KIT/BRAF and PDGFRA/BRAF mutations are rare events in gastrointestinal stromal tumors. *Oncotarget*. 2016 May 24;7(21):30109-18. doi: 10.18632/oncotarget.8768.
77. Zerboni G, Capurso G, **Pillozzi E**, Papi C. Colonic small cell neuroendocrine carcinoma in a patient with long-standing ulcerative colitis treated with azathioprine. *Dig Liver Dis*. 2016 Jul;48(7):822-3. doi: 10.1016/j.dld.2016.03.025.
78. **Pillozzi E**, Bartolazzi A, Fochetti F, Duranti E, Scarpino S, Valeriani M, Moriconi P, Ruco L A case of sinonasal melanoma with unusual primary exon 17 *KIT* D820G mutation. *Applied Immunohistochemistry and Molecular Morphology*. (IF: 2).
79. Signore M, Buccarelli M, **Pillozzi E**, De Luca G, Cappellari M, Fanciulli M, Goeman F, Melucci E, Biffoni M, Ricci-Vitiani L UCN-01 enhances cytotoxicity of irinotecan in colorectal cancer stem-like by impairing DNA damage response. *Oncotarget* 2016. PMID 27286453
80. Iannicelli E, Di Pietropaolo M, **Pillozzi E**, Osti MF, Valentino M, Masoni L, Ferri M. Value of diffusion-weighted MRI and apparent diffusion coefficient measurements for predicting the response of locally advanced rectal cancer to neoadjuvant chemioradiotherapy. *Abdomen radiology* 2016; PMID 27323759
81. Aurello P, Berardi G, Tierno SM, Rampioni Vinciguerra GL, Socciarelli F, Laracca GG, Giulitti D, **Pillozzi E**, Ramacciato G. Influence of perineural invasion in predicting overall survival and disease-free survival in patients with locally advanced gastric cancer. *Am J Surg*. 2016 Jul 29. pii: S0002-9610(16)30367-1. doi: 10.1016/j.amjsurg.2016.05.022
82. Romiti A, Rulli E, **Pillozzi E**, Gerardi C, Roberto M, Legramandi L, Falcone R, Pacchetti I, Marchetti P, Floriani I. Exploring the Prognostic Role of Microsatellite Instability in Patients With Stage II Colorectal Cancer: A Systematic Review and Meta-Analysis. *Clin Colorectal Cancer*. 2016 Aug 31. pii: S1533-0028(16)30154-2. doi: 10.1016/j.clcc.2016.08.007.

83. Iannicelli E, Carbonetti F, Federici GF, Martini I, Caterino S, **Pilozzi E**, Panzuto F, Briani C, David V. Evaluation of the Relationships Between Computed Tomography Features, Pathological Findings, and Prognostic Risk Assessment in Gastrointestinal Stromal Tumors. *J Comput Assist Tomogr*. 2016 Oct 7
84. **Pilozzi E**, Lorenzon L, Lo Baido S, Ferri M, Duranti E, Fochetti F, Mercantini P, Ramacciato G, Balducci G, Ruco L. Left-sided early onset colorectal carcinomas: a sporadic neoplasm with aggressive behavior. *Am J Surg* 2017; 214: 421-427
85. Picchianti-Diamanti A, Laganà B, Cox MC, **Pilozzi E**, Amodeo R, Bove M, Markovic M, Sorgi M, Di Rosa R, Salemi S, Rosado MM, D'Amelio R TCD4pos lymphocytosis in Rheumatoid and Psoriatic Arthritis patients following TNF α blocking agents *Journal of Translational Medicine* 2017; 15:38.
86. Lorenzon L, Ricca L, **Pilozzi E**, Lemoin A, Riggio V, Giudice MT, Mallel G, Fochetti F, Balducci G. Tumor regression grades, K-RAS mutational profile and c-MET in colorectal liver metastases. *Pathol res Pract* 2017; 213:1002-09
87. Panzuto F, Cicchese N, Partelli S, Rinzivillo M, Capurso G, Merola E, Manzoni M, Pucci E, Iannicelli E, **Pilozzi E**, Rossi M, Doglioni C, Falconi M, Delle Fave G. Impact of Ki67 re-assessment at time of disease progression in patients with pancreatic neuroendocrine neoplasms. *Plos One* 2017; 12(6):e0179445
88. Galli G, Purchiaroni F, Lahner E, Sacchi MC, **Pilozzi E**, Corleto VD, Di Giulio E, Annibale B. Time trend occurrence of duodenal intraepithelial lymphocytosis and celiac disease in an open access endoscopic population. *United European Gastroenterology J* 2017; 5: 811-18.
89. Passacantilli I, Panzeri V, Bielli P, Fatini D, **Pilozzi E**, Delle Fave G, Capurso G, Sette C. Alternative polyadenylation of ZEB1 promotes its translation during genotoxic stress in pancreatic cancer cells. *Cell Death Dis* 2017; 8(11):e3168.
90. Sette G, Salvati V, Giordani I, **Pilozzi E**, Quacquareni D, Duranti E, De Nicola F, Pallocca M, Fanciulli M, Falchi M, Pallini R, De Maria R, Eramo A. Conditionally reprogrammed cells (CRC) methodology does not allow the in vitro expansion of patient-derived primary and metastatic lung cancer cells. *Int J Cancer* 2018; 43:88-99.
91. Vannella G, D'Ambra G, **Pilozzi E**, Capurso G, Di Giulio E. Unusual findings in Peutz-Jeghers syndrome: endoscopic and histologic appearance of gastric hamatomatous polyposis with foveolar dysplasia. *Gastrointestinal Endosc*. 2018; doi: 10.1016/j.gie.2018.02.027
92. Pepe G, Di Napoli A, Cippitelli C, Scarpino S, **Pilozzi E**, Ruco L. Reduced lymphotoxin-beta production by tumour cells is associated with loss of follicular dendritic cell phenotype and diffuse growth in follicular lymphoma. *J Pathol Clin Res* 2018; 4:124-134.
93. Antonelli G, Berardi G, Rampioni Vinciguerra GL, Brescia A, Ruggeri M, Mercantini P, Corleto VD, D'Ambra G, **Pilozzi E**, Hassan C, Angeletti S, Di Giulio E Clinical management of endoscopically resected pT1 colorectal cancer. *Endosc Int Open* 2018 , E1462-E1469.
94. Carabotti M, Esposito G, Lahner E, **Pilozzi E**, Conti L, Ranazzi G, Severi C, Bellini M, Annibale B. Gastroesophageal reflux symptoms and microscopic esophagitis in a cohort of consecutive patients affected by atrophic body gastritis: a pilot study. *Scand J Gastroenterol* 2019, 54: 35-40.

95. Falcone R, Romiti A, Filetti M, Roberto M, Righini R, Botticelli A, **Pilozzi E**, Ghidini M, Pizzo C, Mazzuca F, Marchetti P. Impact of tumor site on the prognosis of small bowel adenocarcinoma. *Tumori* 2019 doi: 10.1177/0300891619839297
96. Romiti A, Roberto M, Marchetti P, Di Cerbo A, Falcone R, Campisi G, Ferri M, Balducci G, Ramacciato G, Ruco L, **Pilozzi E** Study of histopathologic parameters to define the prognosis of stage II colon cancer *International Journal of Colorectal Disease* 2019, 34: 905-913.
97. Rampioni Vinciguerra GL, Antonelli G, Citron F, Berardi G, Angeletti S, Baldassarre G, Vecchione A, Di Giulio E, **Pilozzi E**. Pathologist second opinion significantly alters clinical management of pT1 endoscopically resected colorectal cancer. *Virchows Arch.* 2019 Nov;475(5):665-668
98. Magi L, Mazzuca F, Rinzivillo M, Arrivi G, **Pilozzi E**, Prosperi D, Iannicelli E, Mercantini P, Rossi M, Pizzichini P, Laghi A, Signore A, Marchetti P, Annibale B, Panzuto F. Multidisciplinary Management of Neuroendocrine Neoplasia: A Real-World Experience from a Referral Center. *J Clin Med.* 2019 Jun 25;8(6)
99. Capurso G, Gaujoux S, Pescatori LC, Panzuto F, Panis Y, **Pilozzi E**, Terris B, de Mestier L, Prat F, Rinzivillo M, Coriat R, Coulevard A, Delle Fave G, Ruszniewski P. The ENETS TNM staging and grading system accurately predict prognosis in patients with rectal NENs. *Dig Liver Dis.* 2019 Dec;51(12):1725-1730.
100. Terracciano F, Capone A, Montori A, Rinzivillo M, Partelli S, Panzuto F, **Pilozzi E**, Arcidiacono PG, Sette C, Capurso G. MYC up-regulation confers resistance to everolimus and establishes vulnerability to cyclin dependent kinase inhibitors in pancreatic neuroendocrine neoplasms cells. *Neuroendocrinology.* 2020 Jul 2. doi: 10.1159/000509865. Online ahead of print.PMID: 32615570
101. Roberto M, Marchetti P, Arrivi G, Di Pietro FR, Cascinu S, Gelsomino F, Caputo F, Cerma K, Ghidini M, Ratti M, Pizzo C, Ficorella C, Parisi A, Cortellini A, Urbano F, Calandrella ML, Botticelli A, Dell'Aquila E, Minelli A, Fulgenzi C, Montori A, **Pilozzi E**, Mazzuca F. The treatment paradigm of right-sided metastatic colon cancer: harboring BRAF mutation makes the difference. *Int J Colorectal Dis.* 2020 Aug;35(8):1513-1527. doi: 10.1007/s00384-020-03589-9. Epub 2020 May 7. PMID: 32382835
102. Rinzivillo M, Prosperi D, Mazzuca F, Magi L, Iannicelli E, **Pilozzi E**, Franchi G, Laghi A, Annibale B, Signore A, Panzuto F [¹⁸F]FDG-PET/CT and long-term responses to everolimus in advanced neuroendocrine neoplasia. *J Endocrinol Invest.* 2020 Aug 7. doi: 10.1007/s40618-020-01378-3. Online ahead of print.PMID: 32767279
103. Menini S, Iacobini C, de Latouliere L, Manni I, Vitale M, **Pilozzi E**, Pesce C, Cappello P, Novelli F, Piaggio G, Pugliese G Diabetes promotes invasive pancreatic cancer by increasing systemic and tumour carbonyl stress in *Kras^{G12D/+}* mice. *J Exp Clin Cancer Res.* 2020 Aug 10;39(1):152. doi: 10.1186/s13046-020-01665-0.